XELJANZ for Ulcerative Colitis (UC) Pipeline Report 2023: Drug Market Insights and Forecasts, 2019-2032 - Focus on 7 Major Markets
November 23, 2023 11:23 ET
|
Research and Markets
Dublin, Nov. 23, 2023 (GLOBE NEWSWIRE) -- The "XELJANZ Market Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. "XELJANZ Market Drug...
JAK Inhibitors Market Surges as Autoimmune Diseases Demand Cutting-Edge Solutions, 2032F: Revenues for Ruxolitinib, Tofacitinib, Oclacitinib, Baricitinib, Peficitinib, and Other Inhibitor Types
November 01, 2023 08:18 ET
|
Research and Markets
Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The "Global Janus Kinase (JAK) Inhibitors Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global Janus Kinase (JAK)...
Global Tofacitinib Market Research Report 2023
October 17, 2023 05:18 ET
|
Research and Markets
Dublin, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The "Tofacitinib Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global tofacitinib market is expected to grow...
ROSEN, A LEADING LAW FIRM, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – ABBV
May 04, 2022 16:53 ET
|
The Rosen Law Firm PA
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August...
ROSEN, A TOP RANKED FIRM, Encourages AbbVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ABBV
April 30, 2022 11:48 ET
|
The Rosen Law Firm PA
NEW YORK, April 30, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and...
ABBV LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ABBV
April 20, 2022 10:28 ET
|
The Rosen Law Firm PA
NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – ABBV
April 09, 2022 15:06 ET
|
The Rosen Law Firm PA
NEW YORK, April 09, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...